Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2026 | Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment

Elena Zamagni • 25 Sep 2026
IMS 2026
Rare Diseases

Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the importance of accurate imaging and bone marrow assessment in managing solitary plasmacytomas, highlighting the need for proper follow-up and the role of radiotherapy as a first-line treatment option. Dr Zamagni emphasizes the significance of implementing good imaging techniques to prevent major errors in diagnosis and treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elena Zamagni

Longitudinal liquid biopsy versus bone marrow assessment for monitoring MRD in frontline myeloma
1:21
Longitudinal liquid biopsy versus bone marrow assessment for monitoring MRD in frontline myeloma
Elena Zamagni • 25 Sep 2026
Implementing BCMA- & GPRC5D- targeted therapies outside specialist centers: unmet educational needs
1:37
Implementing BCMA- & GPRC5D- targeted therapies outside specialist centers: unmet educational needs
Elena Zamagni • 25 Sep 2026
Real-world insights into the use of belantamab mafodotin-based combinations in R/R MM
1:28
Real-world insights into the use of belantamab mafodotin-based combinations in R/R MM
Elena Zamagni • 25 Sep 2026
Consensus and debate in newly diagnosed multiple myeloma: autoSCT, immunotherapy, & MRD
1:42
Consensus and debate in newly diagnosed multiple myeloma: autoSCT, immunotherapy, & MRD
Elena Zamagni • 25 Sep 2026

Related Videos

Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
3:04
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Phase III CARES: anselamimab mechanism of action in AL amyloidosis
1:18
Phase III CARES: anselamimab mechanism of action in AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Phase II SUMMIT: bezuclastinib reduces symptoms and disease burden in systemic mastocytosis
4:30
Phase II SUMMIT: bezuclastinib reduces symptoms and disease burden in systemic mastocytosis
Prithviraj Bose • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals